依罗卡尼 | 85750-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 依罗卡尼
• 中文别名: 依洛开尼
• 英文名称: 2-[(E)-(4-chlorophenyl)-methylene]-1-[(E)-(3-diisopropylamino)-propyloxyimino]-cyclohexane
• 英文别名: Erocainide；3-[(E)-[(2E)-2-[(4-chlorophenyl)methylidene]cyclohexylidene]amino]oxy-N,N-di(propan-2-yl)propan-1-amine
• CAS: 85750-38-5
• 化学式: C₂₂H₃₃ClN₂O
• 分子量: 376.97
• InChiKey: BURFYXOPVVMBNO-JZYPHBBUSA-N

物化性质

• 沸点：
  481.7±55.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Basic oxime ethers, pharmaceutical compositions possessing antianginal activityand the use of basic oxime ethers for manufactoring medicaments for the treatment of angina
  申请人：EGIS GYOGYSZERGYAR

  公开号：EP0168245A2

  公开（公告）日：1986-01-15

  The invention relates to pharmaceutical compositions possessing valuable antianginal activity. These compositions show higher activity and more favourable therapeutic indices than the reference compound Prenylamine. Preparation of different kinds of pharmaceutical compositions, such as tablets, dragées, capsules and injectable solutions, containing compounds of general formula (I) or their acid addition salts as active ingredients, is disclosed, wherein in formula (I) R is phenyl or 4-chlorophenyl; R1 and R2 each represent hydrogen, methyl or isopropyl: R3 and R4 are hydrogen, or together form a chemical bond; n is an integer from 4 to 6; A means ethylene or trimethylene if n is 4 or 6: or ethylene, if n is 5.

  本发明涉及具有重要抗心绞痛活性的药物组合物。与参考化合物普瑞那敏相比，这些组合物显示出更高的活性和更有利的治疗指数。制备含有通式（I）化合物或其酸加成盐作为活性成分的各种药物组合物，如片剂、片剂、胶囊和注射溶液。 或其酸加成盐作为活性成分，其中式 (I) R 是苯基或 4-氯苯基； R1 和 R2 分别代表氢、甲基或异丙基：R3 和 R4 是氢，或共同形成一个化学键； n 是 4 到 6 的整数； 如果 n 为 4 或 6，A 指乙烯或三亚甲基；如果 n 为 5，A 指乙烯。
• PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX
  申请人：ALTANA Pharma AG

  公开号：EP1341527A1

  公开（公告）日：2003-09-10
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.